Maus, M K H <br/><br/>
KRAS mutations in non-small-cell lung cancer and colorectal cancer: implications for EGFR-targeted therapies.  [electronic resource] 

 -  Lung cancer (Amsterdam, Netherlands)  Feb 2014 
 - 163-7 p.  digital 
<br/><br/> Publication Type: Comparative Study; Journal Article 
<br/><br/><label>ISSN: </label>1872-8332 
<br/><br/><label>Standard No.: </label>10.1016/j.lungcan.2013.11.010  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Antibodies, Monoclonal--therapeutic use<br/>Carcinogenesis--genetics<br/>Carcinoma, Non-Small-Cell Lung--genetics<br/>Colorectal Neoplasms--genetics<br/>DNA Mutational Analysis<br/>ErbB Receptors--immunology<br/>Gene Frequency<br/>Genotype<br/>Humans<br/>Lung Neoplasms--genetics<br/>Molecular Targeted Therapy<br/>Mutation--genetics<br/>Proto-Oncogene Proteins--genetics<br/>Proto-Oncogene Proteins p21(ras)<br/>Smoking--adverse effects<br/>Treatment Outcome<br/>ras Proteins--genetics